NCT01519167View on ClinicalTrials.gov

Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

UltrasoundCT ScansMRIs

Interventions

DRUG

Dexmedetomidine

0.1 - 1.0 mcg/kg/hr IV

DRUG

Midazolam

0.025 - 2 mg/kg IV

DRUG

Fentanyl

0.5 - 3 mcg/kg IV

Trial Locations (11)

15224

Pittsburgh

27710

Durham

33136

Miami

72202

Little Rock

75235

Dallas

84096

Sandy City

92801

Anaheim

94305

Stanford

37232-9070

Nashville

00936-5067

San Juan

00936

San Juan

All Listed Sponsors

lead

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01519167 - Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation | Biotech Hunter | Biotech Hunter